Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-16-015722
Filing Date
2016-05-05
Accepted
2016-05-05 16:27:34
Documents
52
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20160331x10q.htm 10-Q 659649
2 EXHIBIT 31.1 mrtx33116ex311.htm EX-31.1 12451
3 EXHIBIT 31.2 mrtx33116ex312.htm EX-31.2 13383
4 EXHIBIT 32.1 mrtx33116ex321.htm EX-32.1 8359
  Complete submission text file 0001628280-16-015722.txt   2952704

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20160331.xml EX-101.INS 603456
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20160331.xsd EX-101.SCH 23024
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20160331_cal.xml EX-101.CAL 43392
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20160331_def.xml EX-101.DEF 61957
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20160331_lab.xml EX-101.LAB 269764
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20160331_pre.xml EX-101.PRE 146343
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 161624241
SIC: 2834 Pharmaceutical Preparations